Vernalis &r&d) Ltd.

Les Laboratoires Servier

Vernalis Limited

Paul Brough

Christopher John Graham

Alba Macias

Stephen Roughley

Steven Walls

Terance Hart

Rachel Parsons

Guillaume De Nanteuil

Arnaud Le Tiran

Olivier Geneste

James Brooke Murray

I-Jen Chen

James Edward Paul Davidson

Thierry Le Diguarher

Jean-Michel Henlin

Zoltán Szlávik

András Kotschy

Jérôme-Benoît Starck

Imre Fejes

Miklós Nyerges

Anne-Françoise Guillouzic

János Tatai

Claire Walmsley

Johannes W G Meissner

Mark Dodsworth

Johannes Wg Meissner

Andras Kotschy

Christopher Graham

Terrence Hart

Anne-Francoise Guillouzic

Jerome-Benoit Starck

James Edward Davidson

Compound of formula (I): wherein Het, R, R, R, R, R, R, t, p, p', q, and q&#x2032; are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic agent.

Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Azetidine derivatives

Compounds of formula (I): wherein Het, R, R, R, R, R, R, T, p, p', q, and q&#x2032; are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Compounds of formula (I): wherein Het, R, R, R, R, R, R, T, p, p', q, and q&#x2032; are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Wherein Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Formula (I) Wherein Aris optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Aris optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Aris a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms. 

Azetidine derivatives as FAAH inhibitors

Growing community of inventors

Haverhill, United Kingdom

Paul Brough